On this episode of the JVRD Author's Forum podcast, Dr. Nikhil Batra of the Dartmouth School of Medicine discusses "Belzutifan as the Primary Treatment of Bilateral Juxtapapillary Retinal Hemangioblastoma in a Patient With von Hippel–Lindau Disease," published in the May/June 2025 issue of JVRD. 

 Host Dr. Timothy Murray and Dr. Batra discuss how belzutifan, a HIF-2α inhibitor, was used off-label to successfully treat bilateral optic nerve hemangioblastomas in a patient with Von Hippel-Lindau Disease, resulting in significant tumor regression and visual improvement. Hear how this targeted therapy may represent a promising new direction in managing complex retinal tumors that are difficult to treat with traditional approaches.